F-18 16 Alpha-Fluoroestradiol

Phase 2Small molecule

F-18 16 Alpha-Fluoroestradiol is one of 22 small molecule programs targeting Anatomic Stage IV Breast Cancer AJCC v8. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Anatomic Stage IV Breast Cancer AJCC V8Recruiting

Estrogen Receptor PositiveActive, not recruiting

Her2/neu NegativeActive, not recruiting

Anatomic Stage IV Breast Cancer AJCC V8Phase 2

Recruiting

Estrogen Receptor PositivePhase 2

Active, not recruiting

Her2/neu NegativePhase 2

Active, not recruiting

Competition

Competitive Landscape

22 competitors in Anatomic Stage IV Breast Cancer AJCC V8

#DrugCompanyPhaseTrials

Herceptin

Roche

Approved

2 2

Trastuzumab Deruxtecan

AstraZeneca

Phase 3

2 3

Taxol

Teva

Phase 2

4 4

Keytruda

Merck & Co.

Phase 2

3 5

Verzenio

Eli Lilly

Phase 2

3 6

Adriamycin

Pfizer

Phase 2

1 7

Trodelvy

Gilead

Phase 2

1 8

Halaven

Eisai

Phase 2

1 9

Leukine

Sanofi

Phase 2

1 10

Paraplatin

AAvyxa

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Her2/neu Negative

NCT02398773

Q4 2028

Phase 2Recruiting

Anatomic Stage IV Breast Cancer AJCC V8

NCT07112053

Q2 2041

Phase 2Active, not recruiting

Estrogen Receptor Positive

NCT04692103

Clinical

Trials by Indication[1]

Anatomic Stage IV Breast Cancer AJCC v82 trials

A Phase II Study of STEMVAC Vaccine Therapy for Patients With Hormone Receptor Positive Metastatic Breast Cancer

Recruiting·UUniversity of Washington·Phase 2·NCT07112053·40 enrolled

A Phase II Trial of Stereotactic Body Radiation Therapy and Fluoroestradiol Positron Emission Tomography in Patients With Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer

Recruiting·CCity of Hope Medical Center·Phase 2·NCT06260033·18 enrolled

Breast Cancer1 trial

F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy

Terminated·UUniversity of Washington·N/A·NCT02149173·29 enrolled

Desmoid Tumor1 trial

18F-FES PET/CT in Imaging Patients With Desmoid Tumors

Terminated·VVanderbilt-Ingram Cancer Center·Phase 1·NCT02374931·3 enrolled

Estrogen Receptor Positive1 trial

Serial [F-18] Fluoroestradiol (FES) PET Imaging to Evaluate Endocrine-targeted Therapy

Active, not recruiting·UUniversity of Washington·Phase 2·NCT04692103·2 enrolled

HER2/Neu Negative1 trial

[18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients With Newly Diagnosed Metastatic Breast Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02398773·99 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for F-18 16 Alpha-Fluoroestradiol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — F-18 16 Alpha-Fluoroestradiol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for F-18 16 Alpha-Fluoroestradiol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Washington company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Washington

F-18 16 Alpha-Fluoroestradiol

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2028

Q2 2041

Trials by Indication[1]

Anatomic Stage IV Breast Cancer AJCC v82 trials

Breast Cancer1 trial

Desmoid Tumor1 trial

Estrogen Receptor Positive1 trial

HER2/Neu Negative1 trial

References

Drug Info

Quick Facts

Related News